MK-8353
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for MK-8353, covering 2020-04-02 to 2024-11-21. Get the full timeline:
Most recent: Clinical Trial Update: Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) [Phase 1]